Affiliation:
1. Department of Urology The First Affiliated Hospital of Soochow University Suzhou 215006 China
2. Frontiers Science Center for Cell Responses State Key Laboratory of Medicinal Chemical Biology Key Laboratory of Bioactive Materials Ministry of Education and College of Life Sciences Nankai University Tianjin 300071 China
3. Department of Urology Tianjin First Central Hospital Tianjin 300192 China
4. Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy Cancer Institute Xuzhou Medical University Xuzhou Jiangsu 221002 China
Abstract
AbstractImmunotherapy has received widespread attention for its effective and long‐term tumor‐eliminating ability. However, for immunogenic “cold” tumors, such as prostate cancer (PCa), the low immunogenicity of the tumor itself is a serious obstacle to efficacy. Here, this work reports a strategy to enhance PCa immunogenicity by triggering cascade self‐enhanced ferroptosis in tumor cells, turning the tumor from “cold” to “hot”. This work develops a transformable self‐assembled peptide TEP‐FFG‐CRApY with alkaline phosphatase (ALP) responsiveness and glutathione peroxidase 4 (GPX4) protein targeting. TEP‐FFG‐CRApY self‐assembles into nanoparticles under aqueous conditions and transforms into nanofibers in response to ALP during endosome/lysosome uptake into tumor cells, promoting lysosomal membrane permeabilization (LMP). On the one hand, the released TEP‐FFG‐CRAY nanofibers target GPX4 and selectively degrade the GPX4 protein under the light irradiation, inducing ferroptosis; on the other hand, the large amount of leaked Fe2+ further cascade to amplify the ferroptosis through the Fenton reaction. TEP‐FFG‐CRApY‐induced immunogenic ferroptosis improves tumor cell immunogenicity by promoting the maturation of dendritic cells (DCs) and increasing intratumor T‐cell infiltration. More importantly, recovered T cells further enhance ferroptosis by secreting large amounts of interferon‐gamma (IFN‐γ). This work provides a novel strategy for the molecular design of synergistic molecularly targeted therapy for immunogenic “cold” tumors.
Funder
National Natural Science Foundation of China
Fundamental Research Funds for the Central Universities
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献